REPLIGEN CORP Amortization
REPLIGEN CORP (RGEN) reported Amortization of $727.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q/A filed 2024-11-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2024-11-18
- REPLIGEN CORP amortization for the quarter ending 2023-03-31 was $727.00K, a 0.69% increase year-over-year.
- REPLIGEN CORP amortization for the quarter ending 2022-09-30 was $725.00K, a 77.14% decline year-over-year.
- REPLIGEN CORP amortization for the quarter ending 2022-06-30 was $722.00K, a 76.96% decline year-over-year.
- REPLIGEN CORP amortization for the quarter ending 2022-03-31 was $722.00K, a 76.71% decline year-over-year.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month |
|---|---|---|---|
| 2023-03-31 | $727.00K 10-Q/A · filed 2024-11-18 | ||
| 2022-09-30 | $725.00K 10-Q · filed 2022-11-01 | $1.45M derived: sum of 2 quarters · filed 2022-11-01 | $2.17M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $722.00K 10-Q · filed 2022-08-02 | $1.44M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $722.00K 10-Q/A · filed 2024-11-18 | ||
| 2021-09-30 | $3.17M 10-Q · filed 2022-11-01 | $6.30M derived: sum of 2 quarters · filed 2022-11-01 | $9.40M 10-Q · filed 2022-11-01 |
| 2021-06-30 | $3.13M 10-Q · filed 2022-08-02 | $6.23M 10-Q · filed 2022-08-02 | |
| 2021-03-31 | $3.10M 10-Q · filed 2022-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |